Myelofibrosis (MF) is a chronic BCR::ABL1-negative myeloproliferative neoplasm (MPN) characterized by clonal myeloid proliferation, bone marrow fibrosis, extramedullary hematopoiesis, and progressive cytopenias.

cGVHD differs fundamentally from acute GVHD and resembles features of autoimmunity and chronic inflammation-driven fibrosis. The pathogenesis includes three overlapping phases.

This article provides a high-level overview of follicular lymphoma (FL), including diagnosis, treatment options, and unmet needs.

This article provides a high-level overview of the evolution of DLBCL treatment, unmet clinical needs, diagnosis, immunophenotyping, and future therapeutic innovations.

Nemolizumab, when administered every 4 weeks, saw a statistically significant improvement in itch relief and IGA treatment success at Week 16, with results as early as 4 weeks, sustained/improvement through Week 24, and a relatively favorable safety profile.